硬皮病治疗研究进展及治疗指南演变  

Progress in the Treatment of Scleroderma and Evolution of Therapeutic Guidelines

作　　者：杨雪 邹和建[1,2,3,4,5,6,7,8,9,10,11] YANG Xue;ZOU Hejian(Department of Rheumatology and Immunology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China;Rheumatology and Immunology Allergy Research Center of Fudan University, Shanghai 200040, China)

机构地区：[1]复旦大学附属华山医院风湿免疫科,上海200040 [10]中国人类遗传资源管理专家组 [11]中国医药生物技术协会组织生物样本库分会 [2]复旦大学风湿免疫过敏性疾病研究中心,上海200040 [3]复旦大学附属华山医院分子与转化医学研究所 [4]海峡两岸医药卫生交流协会风湿免疫病学专业委员会痛风学组 [5]中国老年医学委员会高尿酸与痛风专家委员会 [6]国际硬皮病临床与研究协作网(inSCAR) [7]世界卫生组织热带病研究所研究伦理论坛WHO/TDRFERCAP指导委员会 [8]国家卫生标准委员会 [9]教育部临床医学专业认证工作委员会

出　　处：《药学进展》2019年第4期261-268,共8页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金(No.81871277,No.81671588);2018年度“华山医院优秀人才培养奖励计划”华菁奖

摘　　要：硬皮病是一组以增厚硬化的皮肤病变为共同表现的自身免疫性疾病,受累组织和器官广泛,多种发病机制参与其中。目前,硬皮病的治疗缺乏明确有效的药物,多以免疫抑制、抗纤维化及对症支持治疗为主,近年来一些针对血管病变的新药物及生物制剂在硬皮病中逐渐得到应用,为硬皮病的治疗提供了新的机遇。对于硬皮病的治疗推荐,近年来也有不断的更新和完善,有利于硬皮病的早期评估及系统治疗。Scleroderma is a group of autoimmune diseases characterized by thickening and hardening of skin lesions. It involves a wide range of tissues and organs, and various mechanisms of pathogenesis. At present, drugs with established effects are lacking for the treatment of scleroderma. Immunosuppression, anti-fibrosis and symptomatic supportive therapy are often used in the treatment of scleroderma. Recently,some new drugs for vascular diseases and some biological agents have been gradually applied in scleroderma, providing new opportunities for treatment. The guidelines for the treatment of scleroderma has also been constantly updated and improved in recent years, which is conducive to the early evaluation and systematic treatment of scleroderma.

关 键 词：硬皮病 治疗进展 指南演变 

分 类 号：R593.25[医药卫生—内科学]